Form 4: Immunome Inc. Chief Technology Officer Acquires 21,000 Shares

Immunome Inc.'s Chief Technology Officer, Philip Tsai, acquired 21,000 shares of common stock at a price of $9.43 per share on November 21, 2024.

Summary

• Philip Tsai, the Chief Technology Officer of Immunome Inc., purchased 21,000 shares of the company's common stock.
• The transaction occurred on November 21, 2024.
• The purchase price was $9.43 per share.
• Following the transaction, Mr. Tsai directly owns 21,000 shares of Immunome Inc. common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a standard insider transaction, which is neither particularly positive nor negative on its own. The purchase by an officer could be seen as a positive sign, but it's not a major event.

Positives

• The purchase of shares by a company officer can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the transactions of company officers.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical of insider trading activity, where company officers buy or sell shares of their own company.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the insider purchase.

Key Dates

Keywords

Immunome Inc., insider trading, stock acquisition, Philip Tsai, Chief Technology Officer, IMNM, SEC Form 4